Abstract
Background
Oral anticoagulants (OAC) are indicated in patients with atrial fibrillation (AF) and high risk of ischemic stroke. However, the introduction of anticoagulation in patients with AF and previous intracerebral hemorrhage (ICH) is controversial. We aimed to better understand the efficacy and safety of OAC in this context and to assess the factors that may influence this decision.
Methods
In a single-center retrospective observational study, patients with AF and ICH who survived hospitalization at a level A Stroke Unit between 2009 and 2018 were included. Patients were followed for two years after discharge. Data were collected regarding the introduction or not of OAC and the occurrence of major thrombotic/hemorrhagic events and death.
Results
Ninety-five patients (75.2 ± 9.9 years) were included and 40 patients (42.1%) started OAC. Patients were more likely to initiate anticoagulation if they had: mechanical prosthetic valves, previous AF (p = 0.005) and previous OAC therapy (p < 0001); and less if they had previous hemorrhagic stroke (p < 0.005). During follow-up, 10.5% had at least one major hemorrhagic event (60% anticoagulated), 20% had at least one major thrombotic event (all non-anticoagulated) and 20% died. The only factor associated with the risk of bleeding was ICH score (OR:2.49 per 1-point increase; 95%CI:1.14–5.46). Patients who initiated anticoagulation had lower mortality than non-anticoagulated (OR:0.296; 95%CI:0.090–0-975). Previous ICH and higher CHA2DS2-VASc were associated with higher mortality.
Conclusion
In this retrospective series, anticoagulation reduced thrombotic events and overall mortality in patients admitted for ICH and AF, without a significant increase in bleeding risk.
Similar content being viewed by others
Data availability
Data were collected after authorization from the São João University Hospital Center. The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Qureshi AI, Mendelow AD, Hanley DF (2009) Intracerebral haemorrhage. Lancet (London, England) 373:1632–1644
Steiner T, Al-Shahi Salman R, Beer R et al (2014) European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke 9:840–855
Li YG, Lip GYH (2018) Anticoagulation resumption after intracerebral hemorrhage. Curr Atheroscler Rep 20:32
van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ (2010) Incidence, case fatality, and functional outcome of intracerebral haemorrhage over time, according to age, sex, and ethnic origin: a systematic review and meta-analysis. The Lancet Neurology 9:167–176
Ariesen MJ, Claus SP, Rinkel GJ, Algra A (2003) Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 34:2060–2065
Peters SAE, Woodward M (2019) Established and novel risk factors for atrial fibrillation in women compared with men. Heart (British Cardiac Society) 105:226–234
Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37:2893–2962
Perreault S, Cote R, White-Guay B, Dorais M, Oussaid E, Schnitzer ME (2019) Anticoagulants in older patients with nonvalvular atrial fibrillation after intracranial hemorrhage. J Stroke 21:195–206
Hindricks G, Potpara T, Dagres N, et al. 2020 (2021) ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). Eur Heart J 1;42(5):373–498.
Murthy SB, Gupta A, Merkler AE et al (2017) Restarting anticoagulant therapy after intracranial hemorrhage: a systematic review and meta-analysis. Stroke 48:1594–1600
Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC (2001) The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke 32(4):891–7
Greenberg SM, Charidimou A (2018) Diagnosis of cerebral amyloid angiopathy: evolution of the Boston Criteria. Stroke 49:491–497
Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361:1139–1151
Pennlert J, Overholser R, Asplund K et al (2017) Optimal timing of anticoagulant treatment after intracerebral hemorrhage in patients with atrial fibrillation. Stroke 48:314–320
Nielsen PB, Larsen TB, Skjoth F, Gorst-Rasmussen A, Rasmussen LH, Lip GY (2015) Restarting anticoagulant treatment after intracranial hemorrhage in patients with atrial fibrillation and the impact on recurrent stroke, mortality, and bleeding: a nationwide cohort study. Circulation 132:517–525
Raparelli V, Proietti M, Cangemi R, Lip GY, Lane DA, Basili S (2017) Adherence to oral anticoagulant therapy in patients with atrial fibrillation. Focus on non-vitamin K antagonist oral anticoagulants. Thrombosis and haemostasis 117:209–18
Sembill JA, Kuramatsu JB, Schwab S, Huttner HB (2019) Resumption of oral anticoagulation after spontaneous intracerebral hemorrhage. Neurological Research and Practice 1
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Ethical approval
The protocol was previously approved by the Ethics Committee of our Institution. Due to the retrospective nature of the study, the Ethics Committee agreed that the submission of informed consent is waived. We have these documentation that can be send in attachment.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Abrantes, C.S., Pintalhão, M., Tavares, S. et al. Anticoagulation after intracerebral hemorrhage in patients with atrial fibrillation: between Scylla and Charybdis. Neurol Sci 43, 2441–2448 (2022). https://doi.org/10.1007/s10072-021-05602-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10072-021-05602-7